simplechiptm human id1 promoter primers Search Results


simplechiptm human id1 promoter primers  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc simplechiptm human id1 promoter primers
Effect of cyclin D1 and <t>Id1</t> on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
Simplechiptm Human Id1 Promoter Primers, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simplechiptm+human+id1+promoter+primers/SimpleChIP+Human+ID1+Promoter+Primers/pmc03192789-81-22-27
Average 93 stars, based on 1 article reviews
simplechiptm human id1 promoter primers - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
id1 promoter primer  (Cell Signaling Technology Inc)
92
Cell Signaling Technology Inc id1 promoter primer
p300‐mediated acetylation is vital for Smad1 oncofunctions. A) IP assay detecting the acetylation of Smad1 in indicated GBM cell lines. B) IP assay indicating Smad1 acetylation is regulated by p300. Indicated cells were transfected with p300 siRNA, followed by IP using anti‐Smad1 antibody and IB using the indicated antibodies. The relative quantification of Smad1 acetylation was listed. C) Schematic diagram of p300‐specific acetylation site prediction of Smad1 and its mutants with unit point or multi‐site mutation of the indicated Lysine (K) residues converted to Arginine (R). D) IP assay detecting the acetylation of Smad1 mutants. U87 cells were transfected with indicated Smad1 constructs, followed by IP using anti‐Flag antibody and IB using the indicated antibodies. The relative Smad1 acetylation was listed under the bands. E) SBE reporter assay monitoring the activity of SMAD responsive transcriptional regulation in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). F) Western blot analysis of <t>ID1</t> expression in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). G) ChIP‐qPCR assay detecting the enrichment of p53 binding to the promoter of ID1 in U87 expressing different Smad1 constructs ( n = 3, ** p < 0.01). H) Cell growth assay of p53 KO cells overexpressing indicated Smad1 constructs. Cells were cultured for 48 h, and followed with a CCK‐8 assay to detect cell number ( n = 6, ** p < 0.01). I) Representative colony formation (left panel) of p53 KO cells overexpressing indicated Smad1 constructs ( n = 3, ** p < 0.01). J) Apoptosis assay of indicated GBM cells. Cells were treated with Dox (2 µM) for 24 h and apoptotic cells were analyzed by FACS ( n = 3, ** p < 0.01). K) Western blot analysis detecting p53 acetylation in indicated GBM cells expressing different Smad1 constructs. The relative quantifications of p53 acetylation were listed. L) Diagram illustrating the relationship among p53, Smad1 and p300 in regulating acetylation of p53 and Smad1. Smad1 binds p53 and p300 via MH1 and MH2 domain, respectively, and destroys the interaction of p53 and p300. MH2 is essential, but MH1 is dispensable for Smad1 mediated p53 acetylation inhibition.
Id1 Promoter Primer, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simplechiptm+human+id1+promoter+primers/SimpleChIP+Human+ID1+5'UTR+Primers/pmc11789598-418-1-7
Average 92 stars, based on 1 article reviews
id1 promoter primer - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
cyclin d1  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc cyclin d1
Effect of <t>cyclin</t> <t>D1</t> and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: <t>CCND1</t> gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
Cyclin D1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simplechiptm+human+id1+promoter+primers/Cyclin+D1+Antibody/pmc03192789-81-14-27
Average 96 stars, based on 1 article reviews
cyclin d1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Expressing, Migration, Transfection, Plasmid Preparation, Standard Deviation, Microarray, Gene Expression, Western Blot, Boyden Chamber Assay, Control, Two Tailed Test

Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Transfection, Plasmid Preparation, Gene Expression, Microarray, Standard Deviation, Control, Two Tailed Test

Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression

Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Expressing, Gene Expression

EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression, Expressing

Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression, Expressing

p300‐mediated acetylation is vital for Smad1 oncofunctions. A) IP assay detecting the acetylation of Smad1 in indicated GBM cell lines. B) IP assay indicating Smad1 acetylation is regulated by p300. Indicated cells were transfected with p300 siRNA, followed by IP using anti‐Smad1 antibody and IB using the indicated antibodies. The relative quantification of Smad1 acetylation was listed. C) Schematic diagram of p300‐specific acetylation site prediction of Smad1 and its mutants with unit point or multi‐site mutation of the indicated Lysine (K) residues converted to Arginine (R). D) IP assay detecting the acetylation of Smad1 mutants. U87 cells were transfected with indicated Smad1 constructs, followed by IP using anti‐Flag antibody and IB using the indicated antibodies. The relative Smad1 acetylation was listed under the bands. E) SBE reporter assay monitoring the activity of SMAD responsive transcriptional regulation in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). F) Western blot analysis of ID1 expression in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). G) ChIP‐qPCR assay detecting the enrichment of p53 binding to the promoter of ID1 in U87 expressing different Smad1 constructs ( n = 3, ** p < 0.01). H) Cell growth assay of p53 KO cells overexpressing indicated Smad1 constructs. Cells were cultured for 48 h, and followed with a CCK‐8 assay to detect cell number ( n = 6, ** p < 0.01). I) Representative colony formation (left panel) of p53 KO cells overexpressing indicated Smad1 constructs ( n = 3, ** p < 0.01). J) Apoptosis assay of indicated GBM cells. Cells were treated with Dox (2 µM) for 24 h and apoptotic cells were analyzed by FACS ( n = 3, ** p < 0.01). K) Western blot analysis detecting p53 acetylation in indicated GBM cells expressing different Smad1 constructs. The relative quantifications of p53 acetylation were listed. L) Diagram illustrating the relationship among p53, Smad1 and p300 in regulating acetylation of p53 and Smad1. Smad1 binds p53 and p300 via MH1 and MH2 domain, respectively, and destroys the interaction of p53 and p300. MH2 is essential, but MH1 is dispensable for Smad1 mediated p53 acetylation inhibition.

Journal: Advanced Science

Article Title: Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53

doi: 10.1002/advs.202402258

Figure Lengend Snippet: p300‐mediated acetylation is vital for Smad1 oncofunctions. A) IP assay detecting the acetylation of Smad1 in indicated GBM cell lines. B) IP assay indicating Smad1 acetylation is regulated by p300. Indicated cells were transfected with p300 siRNA, followed by IP using anti‐Smad1 antibody and IB using the indicated antibodies. The relative quantification of Smad1 acetylation was listed. C) Schematic diagram of p300‐specific acetylation site prediction of Smad1 and its mutants with unit point or multi‐site mutation of the indicated Lysine (K) residues converted to Arginine (R). D) IP assay detecting the acetylation of Smad1 mutants. U87 cells were transfected with indicated Smad1 constructs, followed by IP using anti‐Flag antibody and IB using the indicated antibodies. The relative Smad1 acetylation was listed under the bands. E) SBE reporter assay monitoring the activity of SMAD responsive transcriptional regulation in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). F) Western blot analysis of ID1 expression in U87 cells expressing the indicated constructs ( n = 3, ** p < 0.01). G) ChIP‐qPCR assay detecting the enrichment of p53 binding to the promoter of ID1 in U87 expressing different Smad1 constructs ( n = 3, ** p < 0.01). H) Cell growth assay of p53 KO cells overexpressing indicated Smad1 constructs. Cells were cultured for 48 h, and followed with a CCK‐8 assay to detect cell number ( n = 6, ** p < 0.01). I) Representative colony formation (left panel) of p53 KO cells overexpressing indicated Smad1 constructs ( n = 3, ** p < 0.01). J) Apoptosis assay of indicated GBM cells. Cells were treated with Dox (2 µM) for 24 h and apoptotic cells were analyzed by FACS ( n = 3, ** p < 0.01). K) Western blot analysis detecting p53 acetylation in indicated GBM cells expressing different Smad1 constructs. The relative quantifications of p53 acetylation were listed. L) Diagram illustrating the relationship among p53, Smad1 and p300 in regulating acetylation of p53 and Smad1. Smad1 binds p53 and p300 via MH1 and MH2 domain, respectively, and destroys the interaction of p53 and p300. MH2 is essential, but MH1 is dispensable for Smad1 mediated p53 acetylation inhibition.

Article Snippet: The ID1 promoter primer was purchased from Cell Signaling Technology (89001).

Techniques: Transfection, Quantitative Proteomics, Mutagenesis, Construct, Reporter Assay, Activity Assay, Expressing, Western Blot, ChIP-qPCR, Binding Assay, Growth Assay, Cell Culture, CCK-8 Assay, Apoptosis Assay, Inhibition

Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Expressing, Migration, Transfection, Plasmid Preparation, Standard Deviation, Microarray, Gene Expression, Western Blot, Boyden Chamber Assay, Control, Two Tailed Test

Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Transfection, Plasmid Preparation, Gene Expression, Microarray, Standard Deviation, Control, Two Tailed Test

Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression

Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Expressing, Gene Expression

EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression, Expressing

Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

Journal: BMC Cancer

Article Title: Cyclin D1, Id1 and EMT in breast cancer

doi: 10.1186/1471-2407-11-417

Figure Lengend Snippet: Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

Techniques: Gene Expression, Expressing